A director at Sun Pharmaceuticals Industries sold 34,000 shares at 942.854INR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
Yet to see increased R&D spend in the Specialty portfolio SUNP delivered a strong beat on 1QFY23 earnings, led by broad based growth across business segments (US/Domestic Formulation (DF)/emerging markets (EMs)/RoW). While lower R&D spends has further enhanced margin in 1QFY23. However, the postponement of clinical trials would delay in obtaining potential approvals/subsequent commercial benefit from new chemical entity (NCE) assets. We have raised our FY23/FY24 EPS estimate by 6%/4%, factor...
The independent financial analyst theScreener just lowered the general evaluation of SUN PHARM.INDUSTRIES (IN), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date November 30, 2021, the closing price was INR 753.60 and its...
SUN PHARMA: Domestic Formulation / US (ex-Taro) on steady footing (SUNP IN, Mkt Cap USD26.2b, CMP INR815, TP INR970, 19% Upside, Buy) Enhanced portfolio / Newer markets to drive specialty sales Sun Pharma (SUNP) delivered yet another robust quarterly performance, with the beat on margins led by Domestic Formulation (DF) / Emerging Markets (EM) and sustained momentum in global specialty sales. We raise our earnings estimate by 7%/3% for FY22E/FY23E, factoring in a) a continued ramp-up in...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
SUN PHARMA: Superior performance across segments led to strong earnings beat (SUNP IN, Mkt Cap USD25b, CMP INR773, TP INR900, 16% Upside, Buy) SUNP’s 1QFY22 earnings were well above our expectation, led by over 25% growth in all segments, except API. Steady traction in the Specialty portfolio, recovery in the core portfolio of Branded Generics, new launches in US Generics, and partial benefit of COVID-related products led to strong growth in 1QFY22 earnings. We raise our FY22E/FY23E earn...
PRINCETON, N.J.--(BUSINESS WIRE)-- Sun Pharmaceutical Industries, Inc. (SUN PHARMA), a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. is voluntarily recalling one lot of RIOMET ER™ (metformin hydrochloride for extended-release oral suspension), 500 mg per 5 mL to the consumer level. The reason for the recall is due to the level of N-Nitrosodimethylamine (NDMA), which has been found to be above the allowable Acceptable Daily Intake (ADI) limit established by the U.S. Food and Drug Administration. This press release features multimedia. View the full release here: (Photo: Business...
Global Rally Losing Upside Momentum The global rally appears to be losing steam as the bearish rising wedge patterns we highlighted last week in the MSCI ACWI, ACWI ex-US, EM, and EAFE indexes ended up breaking down. Additionally, the aforementioned indexes and major indexes in Europe, Japan, and Hong Kong have been unable to break above longer-term resistance. While we believe global equities remain vulnerable to a pullback, some near-term consolidation is another possibility. For now we belie...
PRINCETON, N.J.--(BUSINESS WIRE)-- Sun Pharmaceutical Industries, Inc., USA, (SPII),a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (‘together Sun Pharma,’ Reuters: , Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715), announced that it has donated 2.5 million hydroxychloroquine sulfate tablets for use in the United States. Sun Pharma is seeking to enable health care experts meet the growing patient demands for this product as they assess its potential to treat COVID-19 through clinical trials. “At Sun Pharma, we are resolute in our purpose to help people live healthier lives a...
MUMBAI, India & PRINCETON, N.J.--(BUSINESS WIRE)-- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that one of its wholly-owned subsidiaries has launched Riomet ER™ in the U.S. as an adjunct to diet and exercise to improve glycemic control in patients 10 years of age and older with type 2 diabetes mellitus. Riomet ER™ was approved by the U.S. Food and Drug Administration (FDA) on August 29, 2019. Riomet ER™, dosed once daily, is the first and only FDA-a...
Q3FY20 result highlights Consol revs came at Rs81.5bn vs est of Rs82.7bn. Taro sharply below est at Rs10.5bn vs est of Rs12.6bn; Ex-Taro, revs came at Rs69.9bn - inline. Other operating income stood at Rs1.1bn above est of Rs1bn Ex-Taro, US revs grew 11% qoq to ~$220m (Q2 - $197m) vs est $210m. Although mgt noted that there was a nominal degrowth in the base business, 3 new product launches in the qtr, along with specialty drove revs Domestic sales grew 13% yoy vs est of 11%, faster than IP...
PRINCETON, N.J.--(BUSINESS WIRE)-- Sun Dermatology, a division of Sun Pharmaceutical Industries, Inc., USA, which is a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (together “Sun Pharma”), today announced the launch of Take on Acne – a new advertising campaign designed to raise awareness of the profound impact of acne on everyday life, particularly among teenagers and young adults (roughly 12-25 years of age). A common condition, acne affects more than 85% of adolescents and, depending on its severity, persistence and other factors, is highly correlated with psychosocial probl...
SUN PHARMA: Better performance in India/ROW offset by EM/US (SUNP IN, Mkt Cap USD14.5b, CMP INR431, TP INR510, 18% Upside, Buy) WIP for improving specialty portfolio execution; MR strength in DF rising SUNP gradually enhanced traction in its specialty portfolio with some support of seasonality in the quarter. It also intends to fortify MR strength and increase penetration to aid growth in domestic formulations (DF). We lower our FY20/FY21/FY22E EPS estimates by 4%/4%/2% to factor in the...
MUMBAI, India & PRINCETON, N.J.--(BUSINESS WIRE)-- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” including its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries has launched ABSORICA LD™ (isotretinoin) capsules in U.S. for the management of severe recalcitrant nodular acne in patients 12 years of age and older. ABSORICA LD is the only isotretinoin formulation to feature Sun Pharma’s micronization technology, which utilizes micronized particles to optimize absorption at a 20% lo...
Sun Pharma: Halol 483 out; Resolution of issues key for future product approvals (SUNP IN, Mkt Cap USD14.5b, CMP INR430, TP INR515, 20% Upside, Buy) The USFDA inspected Sun Pharma’s (SUNP) Halol facility from 3rd- 13th Dec’19 and has issued form 483 with 8 observations. The observations are largely related to out of specification (OOS), controls on monitoring of data related to the environment, procedure of sampling at end of the filling process, deficiency in aseptic area processing, co...
Q2FY20 result highlights Consol revs came at Rs81.2bn vs est of Rs80.6bn. Taro below est at Rs11.3bn vs est of Rs11.7bn; Ex-Taro, revs came at Rs68.2bn - inline. Other operating income stood at Rs1.7bn above est of Rs1bn Ex-Taro, US revs came sharply lower at ~$197m (Q1 - $282m) vs est $240m; the generic supply contract which the company had during Q4FY19 and Q1 seems to be much higher than expected (~$70-80m vs est $40-45). Mgt noted that there has been no broad-based improvement in generic...
Sun Pharma: In-line; ramp-up of specialty portfolio – WIP (SUNP IN, Mkt Cap USD14.9b, CMP INR440, TP INR515, 17% Upside, Buy) Revenues driven by India/ROW: SUNP's sales increased 16% YoY to INR79.5b (in-line) in 2QFY20, mainly driven by strong growth in India and RoW sales. India sales were up 35% YoY to INR25b (32% of sales), led by the robust outperformance to industry and partially led by a low base. RoW sales were up 49% YoY to USD161m (16% of sales), led by organic growth and the int...
MUMBAI, India & PRINCETON, N.J.--(BUSINESS WIRE)-- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” including its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries has launched Drizalma Sprinkle™ (duloxetine delayed-release capsules) in the U.S. for oral use. Drizalma Sprinkle is a serotonin and norepinephrine reuptake inhibitor (SNRI) designed for the treatment of various neuro-psychiatric and pain disorders in patients who have difficulty swallowing – a problem that is estimated...
PRINCETON, N.J.--(BUSINESS WIRE)-- Sun Ophthalmics, the branded ophthalmic division of Sun Pharmaceuticals Industries Inc, USA, which is a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (Sun Pharma), will present seven poster presentations at the joint annual meeting of the American Academy of Optometry (AAOPT) and the 3rd World Congress of Optometry (WCO) in Orlando, Fla. (Oct. 23-27). The presentations include five posters that add to the growing body of evidence supporting the efficacy of CEQUA™ (cyclosporine ophthalmic solution) 0.09% in the treatment of patients with kerato...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.